Security key
98420X103
X4 PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (XFOR)
CUSIP: 98420X103
Q4 2022 13F Holders as of 31 Dec 2022
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 60,622,175
- Total 13F value
- $60,205,215
- Share change
- +21,807,038
- Put/Call ratio
- 135%
- SEC-reported price per share
- $0.99
- Number of holders
- 52
- Value change
- +$20,545,513
- Number of buys
- 29
- Number of sells
- 20
- Shares outstanding
- 94,372,096
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2022
Institutions
52
Top holders
10
XFOR full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
X4 Pharmaceuticals, Inc SEC filings
X4 Pharmaceuticals, Inc company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98420X103
Recent filing periods:
Ownership snapshot
Top reported holders of XFOR - X4 PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
NEA Management Company, LLC
Disclosed value leader
NEA Management Company, LLC
Comparable rows
15/15
Latest evidence
30 Sep 2022
13F
Lead comparable stake: 6.9%
Showing 1-6 of 15 holder rows.
Quick read
NEA Management Company, LLC leads the comparable SEC ownership view at 6.9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens NEA Management Company, LLC's linked filing trail.
Comparable ownership
Top 5
NEA Management Company, LLC
6.9%
Bain Capital Life Sciences Invest...
6.8%
ORBIMED ADVISORS LLC
5.3%
AXA S.A.
4.4%
VANGUARD GROUP INC
3.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| NEA Management Company, LLC |
13F
Company
|
6.9%
|
$11,155,000
6,523,157 shares
|
— | 30 Sep 2022 |
| Bain Capital Life Sciences Investors, LLC |
13F
Company
|
6.8%
|
$10,926,000
6,389,436 shares
|
— | 30 Sep 2022 |
| ORBIMED ADVISORS LLC |
13F
Company
|
5.3%
|
$8,596,000
5,026,817 shares
|
— | 30 Sep 2022 |
| AXA S.A. |
13F
Company
|
4.4%
|
$7,056,247
4,126,460 shares
|
— | 30 Sep 2022 |
| VANGUARD GROUP INC |
13F
Company
|
3.4%
|
$5,486,000
3,208,103 shares
|
— | 30 Sep 2022 |
| Point72 Asset Management, L.P. |
13F
Company
|
2.7%
|
$4,354,000
2,546,446 shares
|
— | 30 Sep 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2022
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
52
Shares
60,622,175
Rows available
52
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2022 vs Q4 2025 Across Filers
Q4 2025 holders
3
Q4 2022 holders
52
Holder diff
49
| Investor | Q4 2025 Shares | Q4 2022 Shares | Share Diff | Share Chg % | Q4 2025 value | Q4 2022 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend